Clearmind CMND-100 Phase IIa AUD Enrollment
Analysis based on 16 articles · First reported Sep 01, 2026 · Last updated Sep 11, 2026
The news is a modest positive catalyst for Clearmind Medicine, signaling clinical progress in its lead CMND-100 program and potentially supporting the Nasdaq-listed microcap's share price on a sentiment basis. Broader market impact is negligible given the company's small size and the early-stage nature of the trial, with effects largely confined to the biotechnology and psychedelic-therapeutics sector.
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic psychedelic-derived neuroplastogens, announced the initiation of Phase IIa, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). On September 1, 2026, the company reported that six patients had been enrolled to date, with three participants at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C following successful completion of the trial's initial safety part in healthy volunteers. On September 11, 2026, Clearmind announced the enrollment of the first two patients with AUD at Hadassah Medical Center in Jerusalem, marking the first time CMND-100 was administered to a patient with AUD. CEO Adi Zuloff-Shani stated that the enrollment trajectory continues to build positively and that treating the first AUD patients with CMND-100 represents a major step forward. The trial is designed to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with moderate-to-severe AUD. An independent Data and Safety Monitoring Board previously reviewed Part A data and recommended advancing to subsequent parts of the study. Clearmind's intellectual portfolio consists of nineteen patent families, including 32 granted patents.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard